Loading...

SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects

Published
27 Mar 25
Updated
01 May 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-52.8%
7D
-7.3%

Author's Valuation

UK£4.8768.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 01 May 25

Fair value Increased 0.41%

AnalystConsensusTarget has decreased profit margin from 11.3% to 7.9% and increased future PE multiple from 125.4x to 179.6x.

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 2.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 3.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 8.73%

AnalystConsensusTarget has decreased revenue growth from 25.0% to 17.5%, increased profit margin from -18.8% to 11.2%, increased future PE multiple from -69.3x to 121.8x and increased shares outstanding growth rate from 0.0% to 0.0%.